Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBITDA (2016 - 2025)

Ironwood Pharmaceuticals' EBITDA history spans 16 years, with the latest figure at -$77.0 million for Q4 2025.

  • For Q4 2025, EBITDA fell 344.49% year-over-year to -$77.0 million; the TTM value through Dec 2025 reached $14.7 million, down 84.21%, while the annual FY2025 figure was $14.7 million, 84.21% down from the prior year.
  • EBITDA for Q4 2025 was -$77.0 million at Ironwood Pharmaceuticals, down from $75.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $783.9 million in Q4 2023 and bottomed at -$1.1 billion in Q2 2023.
  • The 5-year median for EBITDA is $40.0 million (2021), against an average of $30.9 million.
  • The largest YoY upside for EBITDA was 1504.2% in 2023 against a maximum downside of 2964.58% in 2023.
  • A 5-year view of EBITDA shows it stood at $41.4 million in 2021, then rose by 18.11% to $48.9 million in 2022, then soared by 1504.2% to $783.9 million in 2023, then plummeted by 95.98% to $31.5 million in 2024, then crashed by 344.49% to -$77.0 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's EBITDA are -$77.0 million (Q4 2025), $75.5 million (Q3 2025), and $45.3 million (Q2 2025).